Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA repair mechanisms are critical in BRCA-mutated ovarian cancer (OC) development and progression.
• BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are key mediators of DNA double-strand and single-strand repair, respectively.
• Defects in these repair pathways create vulnerabilities exploitable by targeted therapies.

Purpose of the Study:

• To review how PARP inhibitors leverage cancer-specific homologous recombination repair defects in BRCA-mutated ovarian cancer.
• To discuss the clinical implementation of BRCA testing for patient selection.
• To highlight the therapeutic potential of PARP inhibitors in ovarian cancer.

Main Methods:

• Review of scientific literature on DNA repair, PARP inhibitors, and BRCA mutations in ovarian cancer.
• Analysis of clinical trial data and regulatory approvals for PARP inhibitors.
• Examination of current practices and guidelines for BRCA testing in routine clinical care.

Main Results:

• PARP inhibitors induce synthetic lethality in BRCA-mutated ovarian cancer by exploiting homologous recombination deficiency.
• Olaparib, a first-in-class PARP inhibitor, has received accelerated approval for maintenance treatment in platinum-sensitive relapsed BRCAm OC.
• BRCA testing is essential for identifying patients eligible for PARP inhibitor therapy.

Conclusions:

• PARP inhibitors represent a significant advancement in the targeted treatment of BRCA-mutated ovarian cancer.
• The efficacy of PARP inhibitors is directly linked to the underlying DNA repair defects in cancer cells.
• Integrating BRCA testing into clinical practice is vital for optimizing patient outcomes with PARP inhibitor therapy.